0 %

GeneFoxCub software: The solution to optimize newborn screening

Neonatal screening has become an essential step in the early detection of rare diseases such as Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID). For laboratories, accuracy, speed, and traceability of results are critical to ensuring optimal care for newborns.

GeneFoxCub: Software designed for laboratories

Developed by FoxWare for LaCAR, GeneFoxCub software addresses the specific needs of molecular biology laboratories by offering:

  • Interprétation automatisée des résultats : analyse directe des données de qPCR pour la détection SCID (TREC) et la détection SMA (SMN1).
  • Workflow automation for greater efficiency
  • Compatibility with laboratory equipment
  • Intuitive and secure interface

A reliable and standardized screening solution

By integrating GeneFoxCub software into their workflow, laboratories gain access to a comprehensive screening solution:

  • From dried blood spot (DBS) collection to qPCR amplification,
  • All the way to automated interpretation and reporting.

This approach minimizes the risk of human error, and accelerates clinical decision-making.

Time savings and increased reliability for laboratories

Implementing GeneFoxCub enables medical biology teams to achieve:

  • Significant time savings through rapid and automated result interpretation.
  • Regulatory compliance in accordance with CE-IVD standards.
  • Reduced human error and improved reproducibility of results.

Conclusion

With GeneFoxCub software, newborn testing enters a new era of automation, standardization, and connectivity.
By integrating seamlessly into SCID & SMA detection workflows, the software provides laboratories with a comprehensive, reliable, and compliant screening solution, enabling them to meet the growing demands for speed, traceability, and precision.
GeneFoxCub thus stands out as an essential tool for laboratories aiming to secure and optimize their newborn screening programs.

Learn more about Genefoxcub

Back to all news Back to all news
Contact